Development and characterisation of Affimer binders to 4 leading therapeutic antibodies

Affinity_and_specificity_cropped-1

Antibodies represent established affinity reagents for use in the regulatory bioanalysis of biologics. Yet, these reagents are associated with limitations that often present challenges with supply, stability and batch-to-batch variation on assay performance.

Our new application note outlines our established development and characterisation process for Affimer binders to four of the leading therapeutic antibodies- Trastuzumab, Rituximab, Adalimumab and Ipilimumab- for use as PK assay reagents. Validation of the Affimer binders’ performance showed: 

  • High specificity and reproducible quantification of the therapeutic antibodies within serum
  • Batch-to-batch consistency in production.
  • Identification and development of the binders within a proven 3 month process.

Download the application note by completing the form.

*By registering your email you agree to receive further updates from Avacta Life Sciences about our products and services which are specific to your areas of interest.